First Person Vaccinated During Trial of New Ebola Jab
The trial will test safety and immune responses as more than 1,000 people have died in the outbreak, the World Health Organization said.
- On Friday, Oxford University administered the first human dose of its ChAdOx1 BDBV vaccine to 37-year-old volunteer Ed Hunt, beginning clinical trials targeting the Bundibugyo strain of Ebola.
- The World Health Organization declared a public health emergency of international concern on May 17, 2026, after severe fever cases emerged; more than 1,000 people have died in the DRC and Uganda since May.
- Researchers developed the candidate in just eight weeks using the same technology as the AstraZeneca Covid-19 vaccine, with the Oxford Vaccine Group and Pandemic Sciences Institute leading the effort funded by CEPI and SII.
- Lead Study Doctor Peter Skydmore said, "Vaccinating the first participants in a first-in-human study is always a significant moment," as eligible participants aged 18 to 55 receive one or two doses to evaluate safety.
- Bundibugyo Ebola, primarily carried by fruit bats, spreads through direct contact with infected body fluids; researchers will continue recruiting and vaccinating volunteers over the coming weeks to evaluate immune responses.
26 Articles
26 Articles
In Oxford, England, the first test subject has been inoculated with an experimental vaccine against the Bundibugyo variant of Ebola. Currently, an outbreak of this disease is causing many casualties in the Democratic Republic of Congo because no vaccine exists against it yet. In this first round, fifty healthy people between the ages of 18 and 55 will be injected with the vaccine to see if it is harmless. They will not be exposed to Ebola, but …
CEPI begins first human trial of Bundibugyo Ebola vaccine
The Phase I clinical trial, known as BD-Ebov, will evaluate the safety of the experimental vaccine and its ability to stimulate immune responses in healthy adult volunteers. The post CEPI begins first human trial of Bundibugyo Ebola vaccine appeared first on Premium Times Nigeria.
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
Oxford Begins First Human Trial of Vaccine Targeting Bundibugyo Ebola Strain
A 37-year-old volunteer received the first dose of Oxford University’s experimental ChAdOx1 BDBV vaccine Friday as researchers race to confront an outbreak that has killed ... The post Oxford Begins First Human Trial of Vaccine Targeting Bundibugyo Ebola Strain first appeared on [your]NEWS.
Medical Xpress
First person vaccinated during trial of new Ebola jab
A volunteer was injected Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
Oxford-forskere har gitt den første vaksinen mot Bundibugyo-ebolaviruset. Utprøvingen skjer mens et utbrd øst i Congo har sitt nesten 3000 mennesker og costs 1269 liv.
Coverage Details
Bias Distribution
- 62% of the sources lean Right
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
